touchCONGRESS

Expanding horizons in the treatment of endometrial cancer: How can data from ESGO 2023 guide clinical practice?

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education

This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from GlaxoSmithKline.

This activity is provided by touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Nicole Concin

    Innsbruck Medical University, Innsbruck, Austria

    Prof. Nicole Concin is a gynaecological oncologist and professor of experimental gynaecology at the Innsbruck Medical University. read more

    Prof. Concin completed her medical degree at the Medical University of Vienna, Austria, and completed post-doctoral research in molecular oncology at Stony Brook University, New York, NY, USA. She is certified as a specialist in gynaecology and obstetrics by the Austrian Medical Association and received the Flemish subspecialty certification in gynaecological oncology from the University of Leuven, Belgium.

    Prof. Concin is President of the European Society of Gynaecological Oncology (ESGO), Chair of the Early Drug Development Group of the European Network of Gynaecological Oncological Trial groups (ENGOT), education faculty member for gynaecological cancer of the European Society for Medical Oncology, member of the International Federation of Gynecology and Obstetrics’ Subcommittee on Endometrial Cancer, and board member of the Austrian and German working groups of Gynaecologic Oncology.

    Prof. Concin’s research focuses on gynaecological oncology. She has led multiple translational and clinical research projects worldwide and has provided her expertise in over 75 international clinical trials in gynaecological oncology, several of which she served as principal and global coordinating investigator.

    In recognition of Prof. Concin’s ability and achievements, she has received multiple grants and awards including the Univ.-Prof. Dr. Karl Fellinger Award of the Austrian Cancer Aid. She has also contributed to the field of gynaecological oncology with over 120 publications.

    Prof. Nicole Concin discloses: Consulting/advisory fees from Akesobio, AstraZeneca, Eisai, eTheRNA immunotherapies NV, GlaxoSmithKline, ImmunoGen, Mersana Therapeutics and Seagen. Educational fees from Kartos Therapeutics, Medscape Oncology, MSD and touchIME. Functions in societies as President of ESGO and Chair of ENGOT Early Drug Development Group. Travel grants from Amgen, Genmab and Roche.
    Dr Mansoor Raza Mirza

    Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark

    Dr Mansoor Raza Mirza, MD, is a highly accomplished chief oncologist at the Department of Oncology at Rigshospitalet – Copenhagen University Hospital in Denmark, and also holds the esteemed position of medical director of the Nordic Society of Gynaecological Oncology – Clinical Trial Unit. read more

    With an extensive background in his field, Dr Mirza has held several leadership roles, including his former position as chair of the European Network of Gynaecological Oncological Trial groups, and his current role as vice president of the European Society of Gynaecological Oncology.

    Dr Mirza is also the executive director of the Gynecologic Cancer Intergroup and a distinguished faculty member of both the European Society for Medical Oncology and the European School of Oncology. Over the course of his impressive career spanning more than three decades, Dr Mirza has served as study chair for multiple clinical trials in gynaecological cancer and has authored over 100 publications in his field. His expertise has led to numerous invitations to speak at most of the international oncology congresses.

    Dr Mansoor Raza Mirza discloses: Consulting/advisory/speaker fees from AstraZeneca, BIOCAD, BioNTech, Boehringer Ingelheim, Exelixis, Gilead, GlaxoSmithKline, Karyopharm Therapeutics, Merck, Regeneron, Roche and Zai Lab. Research grants from Apexigen, AstraZeneca, Deciphera, GlaxoSmithKline and Ultimovacs (all institutional, no financial interest). Member of Board of Directors for Karyopharm Therapeutics and Sera Prognostics. Stocks/shares with Karyopharm Therapeutics and Sera Prognostics.
    Dr Sandro Pignata

    Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Naples, Italy

    Dr Sandro Pignata is a medical oncologist and chief of the division of medical oncology of the Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G Pascale in Naples, Italy. read more

    Dr Pignata was born in Naples, Italy. He completed his MD in 1986 at Naples University, and a PhD in gastroenterological science at the University of Rome in 1990. Since 1993, he has been a member of staff at the National Cancer Institute in Naples.

    Dr Pignata is past president of the Multicenter Italian Trials in Ovarian cancer group, past chair of the European Network of Gynaecological Oncological Trial groups, and has been a member of the educational committee of the European Society for Medical Oncology and the Gynecologic Cancer InterGroup.

    Dr Sandro Pignata discloses: Honoraria from AstraZeneca, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme, Pfizer and Roche; and funding from AstraZeneca, GlaxoSmithKline, MSD, Pfizer and Roche.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    Start activity
     
     
    Start activity
     
     
    Start activity
     
     
    Take CE/CME Test

    touchCONGRESS
    Our faculty interpret key data from the congress, complimented by an expert panel discussing what has been presented. Close

    Expanding horizons in the treatment of endometrial cancer: How can data from ESGO 2023 guide clinical practice?

    Useful tips
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Recognize the rationale and importance of molecular characterization in the management of EC
    • Describe the efficacy data for new and emerging agents in treating advanced or recurrent EC
    • Evaluate safety and practical considerations associated with new and emerging agents in treating advanced or recurrent EC and their impact on clinical practice
    Overview

    In this activity, a leading gynaecology expert reviews key developments in the management of endometrial cancer presented at the European Society of Gynaecological Oncology (ESGO) 2023 Congress, and discusses with two leading co-faculty how these data may apply in clinical practice.

    This activity was filmed following ESGO’s 24th European Gynaecological Oncology Congress, Istanbul, Turkey, 28 September–1 October 2023.

    This activity is CE/CME accredited

    To obtain the credit(s) from this activity, please complete this post-activity test.

    Claim Credit

    Course Modules

    Useful tips
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchMDT

    Shifting the focus to locally advanced cervical cancer: Improving patient outcomes through multidisciplinary teamwork

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives

    GO TO ARTICLE

    CONFERENCE HUB

    Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer

    GO TO HUB

    touchEXPERT OPINIONS

    The evolving clinical landscape of biologic therapy for patients with recurrent/metastatic cervical cancer

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Linda Mileshkin, ESMO 2019 – Phase III OUTBACK trial in cervical cancer

    GO TO HUB

    JOURNALS

    Foreword – European Oncology & Haematology, 2017;13(1):

    GO TO ARTICLE

    Topics covered in this activity

    Gynaecological Cancers
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 9 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from GlaxoSmithKline.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 19 October 2023

    Claim Credit
    touchCONGRESS
    Expanding horizons in the treatment of endometrial cancer: How can data from ESGO 2023 guide clinical practice?

    You may also be interested in...

    touchCONGRESS

    Expanding horizons in the treatment of endometrial cancer: How can data from ESGO 2023 guide clinical practice?

    LAUNCH ACTIVITY

    touchPANEL DISCUSSION

    Preventing HPV-associated cancer by maximizing vaccine uptake

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Linda Mileshkin, ESMO 2019 – Phase III OUTBACK trial in cervical cancer

    GO TO HUB

    CONFERENCE HUB

    Gloria Huang, ASCO 2019 – NRG Oncology/Gynecologic Oncology Group 210 trial

    GO TO HUB

    JOURNALS

    Laparoscopic Radical Hysterectomy for Early-stage Cervical Cancer

    GO TO ARTICLE

    JOURNALS

    New Drugs in the Treatment of Germ Cell Tumours

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from GlaxoSmithKline.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 19 October 2023

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72